Skip to main content

Renalytix AI plc Issue of Shares Under the 2020 Employee Share Purchase Plan, PDMR Dealing and Total Voting Rights

Written by Customer Service on . Posted in Public Companies.

NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) — Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that under the Company’s Employee Share Purchase Plan (“the ESPP”), new 17,652 ordinary shares of £0.0025 each in the capital of the Company (“the Ordinary Shares”) have been issued to settle the purchase of 8,826 American Depositary Shares, each representing two Ordinary Shares (“ADSs”) by employees who participated in the ESPP. Further details in relation to the ESPP were contained in the Company’s announcement of 2 September 2020.
O. James Sterling, Chief Financial Officer, participated in the plan and acquired 4,596 ordinary shares (2,298 ADSs) at £4.50 per share ($12.563 per ADS).The purchase of ADSs by certain employees of the Company who are treated as affiliates under U.S. securities laws (including O. James Sterling, Chief Financial Officer) will be settled once certain additional U.S. securities law requirements have been complied with.An application will be made to the London Stock Exchange for the new Ordinary Shares to be admitted to trading on AIM. It is expected that admission of the 17,652 new Ordinary Shares to trading on AIM will become effective on, or around, 9 March 2021 (“Admission”).Total voting rights
Following Admission, the Company will have 72,047,286 Ordinary Shares in issue with each share carrying the right to one vote. The Company has no Ordinary Shares held in treasury. The total number of voting rights in the Company following Admission will therefore be 72,047,286.
For further information, please contact:
About Kidney Disease 
Kidney disease is now recognised as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control and Prevention (CDC) estimates that 15% of US adults, or 37 million people, currently have chronic kidney disease (CKD). Further, the CDC reports that 9 out of 10 adults with CKD do not know they have it and 1 out of 2 people with very low kidney function who are not on dialysis do not know they have CKD*. Kidney disease is referred to as a “silent killer” because it often has no symptoms and can go undetected until a very advanced stage. Each year kidney disease kills more people than breast and prostate cancer. Every day, 13 patients in the United States die while waiting for a kidney transplant.* https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.htmlAbout RenalytixAI
RenalytixAI is a developer of clinical grade, artificial intelligence-enabled in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, and patient stratification for drug clinical trials. For more information, visit renalytixai.comNotification of dealings in shares by PDMRs of the Company: 

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.